Skip to main content
. 2000 Nov 7;97(24):13300–13305. doi: 10.1073/pnas.240221297

Figure 2.

Figure 2

In vivo generation of cytotoxic T cells after injection of DCs presenting HOX11-, PBX1a-, OVA-, and Meis1-derived peptides. (a) DCs isolated from C57BL/6, nontransgenic, and HOX11 transgenic mice were pulsed with IVT HOX11 mRNA and injected into C57BL/6 (●), nontransgenic (■), and transgenic (▴) mice and analyzed for the in vivo generation of anti-HOX11-specific CTLs. Cytolytic activity was assessed with autologous DC targets pulsed with human HOX11 mRNA. Cytolytic activity in C57BL/6 mice (○) after the injection of DCs pulsed with Meis1 IVT mRNA was assessed against autologous DC targets presenting Meis1-derived peptides. (b) Generation of human PBX1-specific CTLs in C57BL/6 (●) and HOX11 transgenic (▴) mice injected with syngeneic DCs pulsed with IVT human PBX1 mRNA. Cytolytic activity was assessed against autologous DC targets presenting human PBX1a-derived peptides. Nonspecific C57BL/6 (○) and HOX11 transgenic (▵) CTL activity was assessed against unpulsed DC targets. (c) The generation of OVA-specific T cells after the injection of OVA-pulsed DCs into C57BL/6 (●), nontransgenic (■), and HOX11 transgenic (●) mice. Cytolytic activity was assessed against autologous DC targets presenting OVA-derived peptides. Nonspecific C57BL/6 (○), nontransgenic (□), and HOX11 transgenic (▵) CTL activity was assessed against EL4 target cells.